Atonco is a clinical-stage radiopharmaceutical company developing innovative radiopharmaceuticals using astatine-211, an alpha-emitting radionuclide for the treatment of cancer. Atonco, founded in 2019, built with an experienced and passionate team, owns exclusive worldwide licenses for the use of an antibody and proprietary innovative radiolabeling technology.
Atonco, based on disruptive and innovative alpha-immunotherapy, meets two goals:
– clinical indications with real unmet needs
– rapidly accessible tumor targets, suited to the short half-life of astatine-211 (7.2h) and with a small size suited to the very short path length of emitted alpha particles.
“Offer cancer patients a longer and a better quality of life.”
Atonco team aims at offering to patients an innovative therapy to destroy the last remaining cancer cells from residual disease left after conventional cancer treatments including radiation therapy, chemotherapy and immunotherapy.
« We believe that alpha-immunotherapy using astatine-211 is very promising in selected clinical indications. Our vision is to confirm the future of alpha-immunotherapy as a promising targeted radiation therapy for better quality and longer lives of patients with cancer.”
Rue du moulin de la Rousselière
44800 Saint Herblain